NCT00125788View on ClinicalTrials.gov

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Sickle Cell AnemiaThalassemia
Interventions
DRUG

L-glutamine

Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.

DRUG

Placebo

Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.

Trial Locations (5)

10461

Jacobi Medical Center, The Bronx

30303

Grady Memorial Hospital, Atlanta

90502

Harbor-UCLA Medical Center, Torrance

90706

Kaiser Permanente, Bellflower

08903

University of Medicine and Dentistry, New Jersey, New Brunswick

All Listed Sponsors
collaborator

FDA Office of Orphan Products Development

FED

lead

Emmaus Medical, Inc.

INDUSTRY

NCT00125788 - L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia | Biotech Hunter | Biotech Hunter